TD Private Client Wealth LLC Sells 2,226 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

TD Private Client Wealth LLC reduced its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 81.9% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 492 shares of the company's stock after selling 2,226 shares during the period. TD Private Client Wealth LLC's holdings in IDEXX Laboratories were worth $203,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of IDXX. FSA Wealth Management LLC purchased a new stake in IDEXX Laboratories in the 3rd quarter worth approximately $25,000. Rialto Wealth Management LLC purchased a new stake in IDEXX Laboratories in the fourth quarter worth $30,000. Retirement Wealth Solutions LLC purchased a new stake in IDEXX Laboratories in the fourth quarter worth $31,000. Kestra Investment Management LLC bought a new stake in IDEXX Laboratories in the fourth quarter valued at $38,000. Finally, Crews Bank & Trust purchased a new position in IDEXX Laboratories during the 4th quarter valued at $41,000. 87.84% of the stock is owned by institutional investors.

Insider Buying and Selling

In other IDEXX Laboratories news, EVP George Fennell sold 9,986 shares of IDEXX Laboratories stock in a transaction on Monday, February 10th. The stock was sold at an average price of $462.53, for a total value of $4,618,824.58. Following the completion of the sale, the executive vice president now owns 8,176 shares of the company's stock, valued at approximately $3,781,645.28. This trade represents a 54.98 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director M Anne Szostak sold 3,000 shares of the business's stock in a transaction on Friday, February 7th. The stock was sold at an average price of $465.94, for a total value of $1,397,820.00. Following the completion of the transaction, the director now owns 3,061 shares of the company's stock, valued at $1,426,242.34. This represents a 49.50 % decrease in their position. The disclosure for this sale can be found here. 2.11% of the stock is currently owned by company insiders.

Remove Ads

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on IDXX shares. Leerink Partners began coverage on shares of IDEXX Laboratories in a research note on Monday, December 2nd. They set an "outperform" rating and a $500.00 target price on the stock. Leerink Partnrs raised IDEXX Laboratories to a "strong-buy" rating in a research report on Monday, December 2nd. Morgan Stanley reduced their target price on IDEXX Laboratories from $559.00 to $550.00 and set an "overweight" rating on the stock in a report on Wednesday, January 29th. Barclays raised their target price on IDEXX Laboratories from $481.00 to $520.00 and gave the company an "overweight" rating in a research note on Tuesday, February 4th. Finally, StockNews.com cut IDEXX Laboratories from a "buy" rating to a "hold" rating in a research note on Tuesday. Four equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, IDEXX Laboratories has an average rating of "Moderate Buy" and an average price target of $533.75.

IDEXX Laboratories Stock Down 1.6 %

IDEXX Laboratories stock traded down $6.67 during mid-day trading on Friday, hitting $415.87. The company had a trading volume of 470,167 shares, compared to its average volume of 581,913. IDEXX Laboratories, Inc. has a 12 month low of $398.50 and a 12 month high of $548.88. The company has a market capitalization of $33.71 billion, a PE ratio of 38.98, a price-to-earnings-growth ratio of 3.41 and a beta of 1.39. The stock's 50 day moving average price is $437.07 and its two-hundred day moving average price is $442.90. The company has a current ratio of 1.31, a quick ratio of 0.95 and a debt-to-equity ratio of 0.28.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.